DiabetesPhase 1NCT01809184
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0287 in Healthy Subjects
A Phase 1 study testing insulin 287 and insulin glargine in people with Diabetes and Diabetes Mellitus, Type 2, run by Novo Nordisk A/S at 1 site in Germany.
Trial summary
This trial is conducted in Europe. The aim of this first human dose trial is to investigate the safety, tolerability, pharmacodynamic (the effect of the investigated drug on the body) and pharmacokinetic (exposure of the trial drug in the body) properties of NNC0148-0000-0287 (insulin 287) in a GIPET® I tablet… Read more about this study
- Who is it for?
- Ages 18 to 55 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Diabetes, Diabetes Mellitus, Type 2
- What is being tested?
- insulin 287 and insulin glargine
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 84 participants
- Where
- 1 siteGermany
- Study dates
- 4 Mar 2013to 6 Sep 2013
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Body mass index 18.0-28.0 kg/m^2
- Subject who is considered to be healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG) and clinical laboratory tests performed during the screening visit, as judged by the investigator
Who cannot join
- Known or suspected hypersensitivity to trial products or related products
- Previous participation in this trial. Participation is defined as randomised
- Presence of clinically significant acute gastrointestinal symptoms (e.g. nausea, vomiting, heartburn or diarrhoea) within 2 weeks prior to dosing, as judged by the investigator
- Any chronic disorder or severe disease which, in the opinion of the investigator, might jeopardise subject's safety or compliance with the protocol
Trial locations and contacts
1 site in 1 country.
About this study
This trial is conducted in Europe. The aim of this first human dose trial is to investigate the safety, tolerability, pharmacodynamic (the effect of the investigated drug on the body) and pharmacokinetic (exposure of the trial drug in the body) properties of NNC0148-0000-0287 (insulin 287) in a GIPET® I tablet formulation in healthy subjects.
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Being tested
- insulin 287, insulin glargine, placebo
- Medical subject headings
- Diabetes Mellitus, Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
insulin 287Drug
Orally administered insulin 287. The subjects will be dosed in the fasting state and receive one single dose followed by a 24-hour euglycaemic glucose clamp.
insulin glargineDrug
Insulin glargine administered subcutaneously (s.c., under the skin) at fixed dose levels.
placeboDrug
Oral placebo adminstered corresponding to insulin 287 treatment
| Study group | Role | What they receive |
|---|---|---|
| Dose level 1 | Experimental | Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group. Receives: Drug: insulin 287; Drug: insulin glargine; Drug: placebo |
| Dose level 2 | Experimental | Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group. Receives: Drug: insulin 287; Drug: insulin glargine; Drug: placebo |
| Dose level 3 | Experimental | Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group. Receives: Drug: insulin 287; Drug: insulin glargine; Drug: placebo |
| Dose level 4 | Experimental | Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group. Receives: Drug: insulin 287; Drug: insulin glargine; Drug: placebo |
| Dose level 5 | Experimental | Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group. Receives: Drug: insulin 287; Drug: insulin glargine; Drug: placebo |
| Dose level 6 | Experimental | Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group. Receives: Drug: insulin 287; Drug: insulin glargine; Drug: placebo |
| Dose level 7 | Experimental | Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group. Receives: Drug: insulin 287; Drug: insulin glargine; Drug: placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of adverse events (AEs)
Measured: As recorded from trial product administration and until completion of Sub-visit 2G (Day 13)
Secondary outcomes (2)
Area under the serum insulin concentration-time curve
Measured: From 0 to 648 hours after a single dose
Area under the glucose infusion rate (GIR)-time curve
Measured: From 0 to 24 hours after a single dose
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Mar 2013 (estimated)
- Study start4 Mar 2013
- Primary completion6 Sep 2013
- Study completion6 Sep 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for DiabetesStudies of the same condition, open and under way.
- More trials run by Novo Nordisk A/SThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 84 participants (actual)
Sponsor and investigators
- Lead sponsor
- Novo Nordisk A/S
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Global Clinical Registry (GCR, 1452), Study director, Novo Nordisk A/S
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01809184
- Sponsor's protocol ID
- NN1956-4014
- Other IDs
- 2012-003048-66, U1111-1132-1018
- Status last verified
- Feb 2017
- First submitted
- 8 Mar 2013
- Last updated
- 1 Mar 2017
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Mar 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0287 in Healthy Subjects
- ClinicalTrials.gov ID
- NCT01809184
- Acronym / sponsor ID
- NN1956-4014
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 84 participants (actual)
- Lead sponsor
- Novo Nordisk A/SIndustry (pharma, biotech, devices)
- Study start
- 4 Mar 2013 (actual)
- Primary completion
- 6 Sep 2013 (actual)
- Study completion
- 6 Sep 2013 (actual)
- First posted
- 12 Mar 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This trial is conducted in Europe. The aim of this first human dose trial is to investigate the safety, tolerability, pharmacodynamic (the effect of the investigated drug on the body) and pharmacokinetic (exposure of the trial drug in the body) properties of NNC0148-0000-0287 (insulin 287) in a GIPET® I tablet formulation in healthy subjects.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 7
| Arm | Type | Receives |
|---|---|---|
| Dose level 1 | Experimental | Drug: insulin 287, Drug: insulin glargine, Drug: placeboEach subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group. |
| Dose level 2 | Experimental | Drug: insulin 287, Drug: insulin glargine, Drug: placeboEach subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group. |
| Dose level 3 | Experimental | Drug: insulin 287, Drug: insulin glargine, Drug: placeboEach subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group. |
| Dose level 4 | Experimental | Drug: insulin 287, Drug: insulin glargine, Drug: placeboEach subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group. |
| Dose level 5 | Experimental | Drug: insulin 287, Drug: insulin glargine, Drug: placeboEach subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group. |
| Dose level 6 | Experimental | Drug: insulin 287, Drug: insulin glargine, Drug: placeboEach subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group. |
| Dose level 7 | Experimental | Drug: insulin 287, Drug: insulin glargine, Drug: placeboEach subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group. |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- Body mass index 18.0-28.0 kg/m^2
- Subject who is considered to be healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG) and clinical laboratory tests performed during the screening visit, as judged by the investigator
Key exclusion criteria (4 listed)
- Known or suspected hypersensitivity to trial products or related products
- Previous participation in this trial. Participation is defined as randomised
- Presence of clinically significant acute gastrointestinal symptoms (e.g. nausea, vomiting, heartburn or diarrhoea) within 2 weeks prior to dosing, as judged by the investigator
- Any chronic disorder or severe disease which, in the opinion of the investigator, might jeopardise subject's safety or compliance with the protocol
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| insulin 287Orally administered insulin 287. The subjects will be dosed in the fasting state and receive one single dose followed by a 24-hour euglycaemic glucose clamp. | Drug | Dose level 1, Dose level 2, Dose level 3, Dose level 4, Dose level 5, Dose level 6, Dose level 7 |
| insulin glargineInsulin glargine administered subcutaneously (s.c., under the skin) at fixed dose levels. | Drug | Dose level 1, Dose level 2, Dose level 3, Dose level 4, Dose level 5, Dose level 6, Dose level 7 |
| placeboOral placebo adminstered corresponding to insulin 287 treatment | Drug | Dose level 1, Dose level 2, Dose level 3, Dose level 4, Dose level 5, Dose level 6, Dose level 7 |
Primary outcome
Number of adverse events (AEs)
Time frame: As recorded from trial product administration and until completion of Sub-visit 2G (Day 13)
2 secondary outcomes
Area under the serum insulin concentration-time curve
Time frame: From 0 to 648 hours after a single dose
Area under the glucose infusion rate (GIR)-time curve
Time frame: From 0 to 24 hours after a single dose
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Mar 2017.
- Clinical Trials at Novo NordiskLink provided by the sponsor.
Related trials for Diabetes
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Effects of Lean Pork Loin Intake on Protein Homeostasis and Glucose Regulation in Prediabetic Adults
Hyperglycaemia (Non Diabetic), Prediabetes
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Global Clinical Registry (GCR, 1452) study director
Novo Nordisk A/S
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing insulin 287 and insulin glargine in people with Diabetes and Diabetes Mellitus, Type 2, run by Novo Nordisk A/S at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Mar 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of adverse events (AEs) (time frame: As recorded from trial product administration and until completion of Sub-visit 2G (Day 13)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Mar 2017.